News Sartorius Stedim Biotech

Equities

DIM

FR0013154002

Mar. 26	Transcript : Sartorius Stedim Biotech S.A. - Shareholder/Analyst Call
Mar. 12	SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating	ZD

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ex-dividend day for final dividend	Apr. 01	FA
Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.	Mar. 26	EQ
Transcript : Sartorius Stedim Biotech S.A. - Shareholder/Analyst Call	Mar. 26
SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating	Mar. 12	ZD
Berenberg: Sartorius Stedim Investors Await 'Several Strong Quarters' for Confidence Boost	Feb. 16	MT
Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them	Feb. 16	EQ
Sartorius Stedim Biotech releases Universal Registration Document 2023	Feb. 16	EQ
Sartorius Stedim Biotech: Information on Document Availability	Feb. 16	EQ
Sartorius gains despite halving dividend	Feb. 09	DP
Sartorius Stedim Biotech S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Sartorius Stedim: dividend set for 2023	Feb. 08	CF
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting	Feb. 07	EQ
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15	Feb. 07	DP
Debt reduction: Sartorius sells shares - Stedim with capital increase	Feb. 07	DP
Sartorius Stedim Biotech Shares Fall After Capital Increase	Feb. 07	DJ
Sartorius Stedim Biotech Completes $1.3 Billion Capital Increase	Feb. 07	DJ
Sartorius Stedim: private placement of 5.15 million shares	Feb. 07	CF
Germany's Sartorius Raises EUR200 Million Via Share Issue	Feb. 07	MT
Sartorius Stedim Biotech Raises EUR1.2 Billion in Fresh Capital from Share Sale	Feb. 07	MT
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights	Feb. 06	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SARTORIUS STEDIM BIOTECH : FY23: Updated mid-term outlook offers much-valued ‘certainty’

January 30, 2024 at 11:54 am EST